期刊文献+

医药企业专利倾向研究 被引量:4

Patent Propensity in Drug Enterprise
原文传递
导出
摘要 医药企业可以通过保密和专利等保护其创新成果。专利倾向是对创新成果申请专利保护的倾向。通过对文献的研究,分析药品专利倾向的影响因素。同时,以立普妥为例,分析药品专利倾向与药品专利申请量之间的关系。研究表明:医药企业的专利倾向越高,对医药产品的创新成果保护越好,药品专利申请量越多。结合经验及实例,从市场、企业以及行业的角度分析专利倾向的重要性,旨在为医药企业的专利倾向方面提供决策依据,提高医药企业的活力和市场竞争力,同时为我国医药企业创新成果保护提供理论依据。
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2016年第4期507-511,共5页 Chinese Journal of Pharmaceuticals
基金 黑龙江省社会科学研究规划年度项目:面向信息需求的医药企业专利战略研究(No.14B017) 黑龙江省应用技术研究与开发计划项目:创新驱动下的黑龙江省医药企业专利战略研究(No.GB14D410)
  • 相关文献

参考文献19

  • 1Scherer FM. The propensity to patent [J]. Int J lnd Organization, 1983, 1 (1): 107-128.
  • 2Arundel A, Kabla I. What percentage of innovations are patented? Empirical estimates for European firms [J]. Res Policy, 1998, 27(2): 127-141.
  • 3Holgersson M. Patent management in entrepreneurial SMEs: a literature review and an empirical study of innovation appropriation, patent propensity, and motives [J]. R&D Manage, 2013, 43 ( 1 ) : 21-36.
  • 4Heger D, Zaby AK. Giving away the game? The impact of the disclosure effect on the patenting decision [EB/OL]. http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2014677.
  • 5Mansfield E, Patents and innovation: an empirical study [J], Manage Sci, 1986, 32 (2) : 173-181.
  • 6Granstrand O. The economics and management of intellectualproperty: towards intellectual capitalism [J]. Genetics, 2000, 36(1): 172-173.
  • 7Hoffman K, Parejo M, Bessant J, et al. Small firms, R&D, technology and innovation in the UK: a literature review [J]. Technovation, 1998, 18 (1) : 39-55.
  • 8De Rassenfosse G. How SMEs exploit their intellectual property assets: evidence from survey data [J]. Small Business Economics, 2012, 39 (2) : 437-452.
  • 9Brouwer E, Kleinknecht A. Innovative output, and a firm's propensity to patent: An exploration of CIS micro data [J]. Res Policy, 1999, 28 (6) : 615-624.
  • 10Nicholas T. Did R&D firms used to patent? Evidence from the first innovation surveys [J]. JEcon History, 2011, 71 (4) : 1032-1059.

二级参考文献14

  • 1WARNER LAMBERT CO. 2-(aminocarbonyl-pyrrolyl)-4-hydroxy-6-oxo- tetra:hydro-pyran derivs.- having hypolipidaemic and hypoc-holesterolaemic activity[P].US4681893A,1987.
  • 2WARNER LAMBERT CO. New cpd.for treating hypercholesterolaemia -(R-(R,R)-2- and (2R-trans)-5-(1-methyl-ethyl-3-phenyl-4-((phenylamino)-carbonyl)-1H-pyrrole-heptanoic acid[P].US5273995A,1993.
  • 3WARNER LAMBERT CO. Stable oral compositions for treating hypercholesterolaemia and hyperlipidaemia - contain HMG CoA inhibitor which is acid-sensitive substd.pyran ring opened acid form of substd.pyrrolyl carboxamide stabilised with metal salt,esp.calcium carbonate[P].US5686104A,1997.
  • 4WARNER LAMBERT CO. Stable oral compositions for treating hypercholesterolaemia and hyperlipidaemia - contain HMG CoA inhibitor which is acid-sensitive substd.pyran ring opened acid form of substd.pyrrolyl carboxamide stabilised with metal salt,esp.calcium carbonate[P].US6126971A,2000.
  • 5WARNER LAMBERT CO. New crystalline forms of atorvastatin (hypolipidaemic agent)- has good filtering and drying properties,and better purity and stability than amorphous form[P].US5969156C1,2006.
  • 6WARNER LAMBERT CO. Pharmaceutical Compositions of Atorvastatin[P].US20040247673A1,2004.
  • 7WARNER LAMBERT CO. Pharmaceutical Compositions of Atorvastatin[P].US20040253305A1,2004.
  • 8PFIZER INC. Use of a synergistic combination of atorvastatin and antihypertensive agent for treating angina pectoris and atherosclerosis[P].WO9911260A1,2000.
  • 9PFIZER INC. Composition for treatment of vascular diseases comprising statin and carboxyalkylether combinations[P].WO9930704A1,1999.
  • 10PFIZER INC. Use of a synergistic combination of atorvastatin and antihypertensive agent for treating angina pectoris and atherosclerosis[P].WO9911260A1,1999.

共引文献3

同被引文献28

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部